<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Health & Wellness Monthly Review ‚Äî January 2026</title>
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Playfair+Display:ital,wght@0,600;0,700;0,800;1,600&display=swap" rel="stylesheet">
  <style>
    *, *::before, *::after { margin: 0; padding: 0; box-sizing: border-box; }

    :root {
      --bg: #fafaf9;
      --surface: #ffffff;
      --text: #1a1a1a;
      --text-secondary: #555;
      --text-muted: #888;
      --border: #e8e5e1;
      --accent-primary: #db2777;
      --accent-secondary: #0891b2;
      --accent-tertiary: #059669;
      --accent-highlight: #7c3aed;
      --serif: 'Playfair Display', Georgia, serif;
      --sans: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
      --shadow-sm: 0 1px 3px rgba(0,0,0,0.04), 0 1px 2px rgba(0,0,0,0.06);
      --shadow-md: 0 4px 12px rgba(0,0,0,0.06), 0 2px 4px rgba(0,0,0,0.04);
      --shadow-lg: 0 10px 30px rgba(0,0,0,0.08);
      --radius: 8px;
      --green: #16a34a;
    }

    html { font-size: 16px; scroll-behavior: smooth; }

    body {
      font-family: var(--sans);
      background: var(--bg);
      color: var(--text);
      line-height: 1.65;
      -webkit-font-smoothing: antialiased;
    }

    .masthead {
      background: var(--surface);
      border-bottom: 1px solid var(--border);
      position: relative;
    }

    .masthead-inner {
      max-width: 900px;
      margin: 0 auto;
      padding: 2.5rem 1.5rem 2rem;
      text-align: center;
    }

    .masthead .overline {
      font-family: var(--sans);
      font-size: 0.7rem;
      font-weight: 600;
      letter-spacing: 0.2em;
      text-transform: uppercase;
      color: var(--text-muted);
      margin-bottom: 0.75rem;
    }

    .masthead h1 {
      font-family: var(--serif);
      font-size: clamp(2rem, 5vw, 3rem);
      font-weight: 800;
      line-height: 1.1;
      color: var(--text);
      margin-bottom: 0.5rem;
    }

    .masthead .edition-date {
      font-family: var(--sans);
      font-size: 0.95rem;
      font-weight: 500;
      color: var(--text-secondary);
    }

    .masthead .edition-sub {
      font-size: 0.8rem;
      color: var(--text-muted);
    }

    .divider-bar {
      width: 60px;
      height: 3px;
      background: var(--accent-primary);
      margin: 1rem auto 0;
      border-radius: 2px;
    }

    .nav-bar {
      display: flex;
      justify-content: center;
      align-items: center;
      gap: 0;
      background: var(--surface);
      border-bottom: 1px solid var(--border);
      font-family: var(--sans);
      font-size: 0.8rem;
      font-weight: 500;
      letter-spacing: 0.04em;
      flex-wrap: wrap;
    }

    .nav-bar a {
      text-decoration: none;
      color: var(--text-muted);
      padding: 0.7rem 1rem;
      border-bottom: 2px solid transparent;
      transition: color 0.2s ease, border-color 0.2s ease;
    }

    .nav-bar a.active {
      color: var(--accent-primary);
      border-bottom-color: var(--accent-primary);
    }

    .nav-bar a:hover:not(.active) {
      color: var(--text-secondary);
    }

    .sector-tabs {
      display: flex;
      justify-content: center;
      gap: 0.5rem;
      padding: 1rem 1.5rem;
      background: var(--bg);
      flex-wrap: wrap;
    }

    .sector-tab {
      font-family: var(--sans);
      font-size: 0.7rem;
      font-weight: 600;
      letter-spacing: 0.05em;
      text-transform: uppercase;
      text-decoration: none;
      padding: 0.5em 1em;
      border-radius: 20px;
      border: 1px solid var(--border);
      color: var(--text-secondary);
      background: var(--surface);
      transition: all 0.2s;
    }

    .sector-tab:hover {
      border-color: var(--text-secondary);
    }

    .sector-tab.active {
      background: var(--accent-primary);
      color: #fff;
      border-color: var(--accent-primary);
    }

    .container {
      max-width: 900px;
      margin: 0 auto;
      padding: 2rem 1.5rem 4rem;
    }

    .section {
      margin-bottom: 3rem;
    }

    .section-header {
      display: flex;
      align-items: center;
      gap: 0.75rem;
      margin-bottom: 1.5rem;
      padding-bottom: 0.75rem;
      border-bottom: 2px solid var(--border);
    }

    .section-icon {
      width: 40px;
      height: 40px;
      border-radius: 10px;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 1.2rem;
      flex-shrink: 0;
    }

    .section-icon.primary { background: #fce7f3; }
    .section-icon.secondary { background: #cffafe; }
    .section-icon.tertiary { background: #d1fae5; }
    .section-icon.highlight { background: #ede9fe; }

    .section-title {
      font-family: var(--serif);
      font-size: 1.35rem;
      font-weight: 700;
      letter-spacing: -0.01em;
    }

    .section-title.primary { color: var(--accent-primary); }
    .section-title.secondary { color: var(--accent-secondary); }
    .section-title.tertiary { color: var(--accent-tertiary); }
    .section-title.highlight { color: var(--accent-highlight); }

    .stat-grid {
      display: grid;
      grid-template-columns: repeat(4, 1fr);
      gap: 1rem;
      margin-bottom: 2rem;
    }

    @media (max-width: 640px) {
      .stat-grid { grid-template-columns: repeat(2, 1fr); }
    }

    .stat-card {
      background: var(--surface);
      border: 1px solid var(--border);
      border-radius: var(--radius);
      padding: 1.25rem;
      text-align: center;
      box-shadow: var(--shadow-sm);
    }

    .stat-value {
      font-family: var(--serif);
      font-size: 1.75rem;
      font-weight: 800;
      color: var(--accent-primary);
      line-height: 1.1;
    }

    .stat-label {
      font-size: 0.7rem;
      font-weight: 500;
      color: var(--text-muted);
      margin-top: 0.35rem;
      text-transform: uppercase;
      letter-spacing: 0.05em;
    }

    .highlight-box {
      background: linear-gradient(135deg, #fce7f3 0%, #d1fae5 100%);
      border: 1px solid var(--border);
      border-radius: var(--radius);
      padding: 1.5rem;
      margin-bottom: 1.5rem;
    }

    .highlight-title {
      font-family: var(--serif);
      font-weight: 700;
      font-size: 1.1rem;
      margin-bottom: 0.75rem;
      color: var(--text);
    }

    .highlight-box p {
      font-size: 0.9rem;
      color: var(--text-secondary);
      line-height: 1.6;
    }

    .highlight-box strong {
      color: var(--text);
    }

    .cards {
      display: grid;
      gap: 1rem;
    }

    .card {
      background: var(--surface);
      border: 1px solid var(--border);
      border-radius: var(--radius);
      padding: 1.25rem 1.5rem;
      box-shadow: var(--shadow-sm);
      transition: box-shadow 0.2s ease, transform 0.2s ease;
    }

    .card:hover {
      box-shadow: var(--shadow-md);
      transform: translateY(-1px);
    }

    .card-headline {
      font-family: var(--serif);
      font-size: 1.05rem;
      font-weight: 700;
      line-height: 1.35;
      margin-bottom: 0.4rem;
      color: var(--text);
    }

    .card-body {
      font-size: 0.9rem;
      color: var(--text-secondary);
      line-height: 1.6;
    }

    .card-tag {
      display: inline-block;
      font-size: 0.65rem;
      font-weight: 600;
      letter-spacing: 0.1em;
      text-transform: uppercase;
      padding: 0.2em 0.6em;
      border-radius: 4px;
      margin-bottom: 0.6rem;
    }

    .card-tag.primary { background: #fce7f3; color: var(--accent-primary); }
    .card-tag.secondary { background: #cffafe; color: var(--accent-secondary); }
    .card-tag.tertiary { background: #d1fae5; color: var(--accent-tertiary); }
    .card-tag.highlight { background: #ede9fe; color: var(--accent-highlight); }

    .card.featured {
      border-left: 4px solid var(--accent-primary);
      padding-left: 1.5rem;
    }

    .bottom-line {
      background: var(--text);
      color: #fff;
      border-radius: var(--radius);
      padding: 2rem;
      box-shadow: var(--shadow-lg);
    }

    .bottom-line .section-header {
      border-bottom-color: rgba(255,255,255,0.15);
      margin-bottom: 1rem;
      padding-bottom: 0.5rem;
    }

    .bottom-line .section-icon { background: rgba(255,255,255,0.12); }
    .bottom-line .section-title { color: #fff; }

    .bottom-line p {
      font-family: var(--serif);
      font-size: 1.1rem;
      font-style: italic;
      line-height: 1.75;
      color: rgba(255,255,255,0.9);
    }

    .footer {
      text-align: center;
      padding: 2rem 1.5rem 3rem;
      font-size: 0.75rem;
      color: var(--text-muted);
      border-top: 1px solid var(--border);
      max-width: 900px;
      margin: 0 auto;
    }
  </style>
</head>
<body>

  <nav class="nav-bar">
    <a href="index.html">Today's Briefing</a>
    <a href="vc-review.html">VC Review</a>
    <a href="archive.html">Archive</a>
  </nav>

  <div class="sector-tabs">
    <a href="vc-review.html" class="sector-tab">üí∞ VC</a>
    <a href="ai-review.html" class="sector-tab">ü§ñ AI</a>
    <a href="longevity-review.html" class="sector-tab">üß¨ Longevity</a>
    <a href="health-wellness-review.html" class="sector-tab active">üíä Health</a>
    <a href="space-review.html" class="sector-tab">üöÄ Space</a>
    <a href="energy-review.html" class="sector-tab">‚ö° Energy</a>
    <a href="sports-entertainment-review.html" class="sector-tab">üé¨ Sports & Entertainment</a>
  </div>

  <header class="masthead">
    <div class="masthead-inner">
      <div class="overline">Monthly Intelligence Brief</div>
      <h1>Health & Wellness Review</h1>
      <div class="edition-date">January 2026 Edition</div>
      <div class="edition-sub">GLP-1 Drugs ¬∑ FDA Approvals ¬∑ Clinical Breakthroughs ¬∑ What to Watch</div>
      <div class="divider-bar"></div>
    </div>
  </header>

  <main class="container">

    <!-- OVERVIEW -->
    <section class="section" id="overview">
      <div class="section-header">
        <div class="section-icon primary">üìä</div>
        <h2 class="section-title primary">Market Overview</h2>
      </div>

      <div class="stat-grid">
        <div class="stat-card">
          <div class="stat-value">24%</div>
          <div class="stat-label">Retatrutide Weight Loss</div>
        </div>
        <div class="stat-card">
          <div class="stat-value">180</div>
          <div class="stat-label">Sepsis Trial Patients</div>
        </div>
        <div class="stat-card">
          <div class="stat-value">98%</div>
          <div class="stat-label">India CRISPR Cost Savings</div>
        </div>
        <div class="stat-card">
          <div class="stat-value">$220M</div>
          <div class="stat-label">Healthier Capital Fund I</div>
        </div>
      </div>

      <div class="highlight-box">
        <div class="highlight-title">üî• The Big Story</div>
        <p>The GLP-1 drug revolution continues with <strong>Retatrutide showing up to 24% body weight loss</strong> ‚Äî the most powerful weight loss drug ever in trials. Suzetrigine (Journavax) became the <strong>first opioid-free painkiller</strong> to receive FDA approval, while breakthrough sepsis and cancer vaccine trials showed promising results.</p>
      </div>
    </section>

    <!-- GLP-1 DRUGS -->
    <section class="section" id="glp1">
      <div class="section-header">
        <div class="section-icon secondary">üíâ</div>
        <h2 class="section-title secondary">GLP-1 Weight Loss Drugs</h2>
      </div>

      <div class="cards">
        <article class="card featured">
          <span class="card-tag secondary">Game Changer</span>
          <h3 class="card-headline">Retatrutide: 24% Weight Loss ‚Äî Most Powerful Ever</h3>
          <p class="card-body">Triple agonist (GIP/GLP-1/Glucagon) showing up to <strong>24% body weight loss</strong> in Phase 3 trials ‚Äî SUPERIOR to Ozempic/Wegovy. "This will likely be the most powerful weight loss drug ever approved." (NEJM 2023)</p>
        </article>

        <article class="card featured">
          <span class="card-tag primary">Market Leader</span>
          <h3 class="card-headline">Mounjaro vs Ozempic: The Data</h3>
          <p class="card-body">Mounjaro targets <strong>two hormones</strong> (GLP-1 + GIP) vs Ozempic's one. Real-world data suggests Mounjaro leads to greater weight loss for many patients. Eli Lilly launched Mounjaro in India (Aug 2025).</p>
        </article>

        <article class="card">
          <span class="card-tag tertiary">Orforglipron</span>
          <h3 class="card-headline">Chugai: Oral GLP-1 FDA Approval Expected</h3>
          <p class="card-body">Chugai Pharmaceutical reports strong overseas sales with FDA approval for obesity drug <strong>orforglipron</strong> expected to be the next big draw ‚Äî an oral alternative to injectable GLP-1s.</p>
        </article>
      </div>
    </section>

    <!-- FDA APPROVALS -->
    <section class="section" id="fda">
      <div class="section-header">
        <div class="section-icon tertiary">‚úÖ</div>
        <h2 class="section-title tertiary">FDA Approvals & Breakthroughs</h2>
      </div>

      <div class="cards">
        <article class="card featured">
          <span class="card-tag tertiary">Opioid-Free</span>
          <h3 class="card-headline">Suzetrigine (Journavax): First Opioid-Free Painkiller</h3>
          <p class="card-body">First NaV1.8 blocker to win FDA approval (early 2025). Trials showed <strong>opioid-level pain relief</strong> for acute and post-surgical pain but <strong>without respiratory depression, sedation, or addiction risk</strong>.</p>
        </article>

        <article class="card featured">
          <span class="card-tag highlight">Fast Track</span>
          <h3 class="card-headline">IHL-42X for Sleep Apnea Gets FDA Fast Track</h3>
          <p class="card-body">IXHL's drug candidate IHL-42X received <strong>Fast Track designation</strong> (Dec 2025) for obstructive sleep apnea treatment, expediting development and approval process.</p>
        </article>

        <article class="card">
          <span class="card-tag secondary">Sepsis</span>
          <h3 class="card-headline">Breakthrough Sepsis Drug Shows Promise in Phase II</h3>
          <p class="card-body">Australian researchers' carbohydrate-based treatment showed promising results in <strong>180-patient Phase II trial</strong>, calming dangerous immune reactions in sepsis patients.</p>
        </article>

        <article class="card">
          <span class="card-tag primary">Cancer Vaccine</span>
          <h3 class="card-headline">Transgene TG4050: Personalized Cancer Vaccine</h3>
          <p class="card-body">French biotech Transgene released Phase I data showing <strong>"striking results"</strong> for individualized cancer vaccine TG4050 in high-risk head and neck cancer patients.</p>
        </article>
      </div>
    </section>

    <!-- WHAT TO WATCH -->
    <section class="section" id="watch">
      <div class="section-header">
        <div class="section-icon highlight">üîÆ</div>
        <h2 class="section-title highlight">What to Watch in February 2026</h2>
      </div>

      <div class="cards">
        <article class="card">
          <p class="card-body">
            üíä <strong>Retatrutide Phase 3 Completion</strong> ‚Äî Most powerful weight loss drug approval timeline<br><br>
            üß¨ <strong>More CRISPR Therapies</strong> ‚Äî Following Baby KJ's cure, expansion expected<br><br>
            üíâ <strong>Oral GLP-1 Approvals</strong> ‚Äî Orforglipron and competitors seeking FDA nod<br><br>
            üè• <strong>Sepsis Drug Phase III</strong> ‚Äî Australian breakthrough advancing to larger trials<br><br>
            üéØ <strong>Personalized Cancer Vaccines</strong> ‚Äî Transgene TG4050 next data readouts
          </p>
        </article>
      </div>
    </section>

    <!-- BOTTOM LINE -->
    <section class="section" id="bottomline">
      <div class="bottom-line">
        <div class="section-header">
          <div class="section-icon">‚ö°</div>
          <h2 class="section-title">Bottom Line</h2>
        </div>
        <p>The GLP-1 revolution is just getting started. Retatrutide's 24% weight loss could reshape the obesity market entirely. The first opioid-free painkiller could help address the addiction crisis. Personalized cancer vaccines and CRISPR cures are moving from theoretical to clinical. India's 98% cost reduction in gene therapy could democratize access globally. Healthcare innovation is accelerating on multiple fronts simultaneously.</p>
        <p style="margin-top: 1rem; font-weight: 700; font-style: normal;">The best healthcare innovations of 2025 will seem quaint by 2030. This is just the beginning.</p>
      </div>
    </section>

  </main>

  <footer class="footer">
    <p>Health & Wellness Monthly Review ¬∑ Compiled by Sanbot ¬∑ January 2026</p>
    <p>Next edition: February 2026</p>
  </footer>

</body>
</html>
